3,700 Shares in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Bought by Jacobi Capital Management LLC

Jacobi Capital Management LLC purchased a new position in shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) during the first quarter, Holdings Channel reports. The institutional investor purchased 3,700 shares of the biopharmaceutical company’s stock, valued at approximately $31,000.

A number of other institutional investors have also modified their holdings of SRNE. BlackRock Inc. lifted its holdings in Sorrento Therapeutics by 17.3% during the fourth quarter. BlackRock Inc. now owns 17,619,678 shares of the biopharmaceutical company’s stock worth $120,253,000 after acquiring an additional 2,603,120 shares during the period. STA Wealth Management LLC lifted its holdings in Sorrento Therapeutics by 250.0% during the fourth quarter. STA Wealth Management LLC now owns 577,500 shares of the biopharmaceutical company’s stock worth $3,941,000 after acquiring an additional 412,500 shares during the period. Wells Fargo & Company MN lifted its holdings in Sorrento Therapeutics by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 1,020,563 shares of the biopharmaceutical company’s stock worth $6,965,000 after acquiring an additional 303,959 shares during the period. Virtu Financial LLC bought a new stake in Sorrento Therapeutics during the fourth quarter worth $1,787,000. Finally, Northern Trust Corp lifted its holdings in Sorrento Therapeutics by 9.1% during the fourth quarter. Northern Trust Corp now owns 2,895,917 shares of the biopharmaceutical company’s stock worth $19,765,000 after acquiring an additional 240,852 shares during the period. Institutional investors and hedge funds own 27.02% of the company’s stock.

Shares of Sorrento Therapeutics stock opened at $8.73 on Friday. The stock’s fifty day simple moving average is $7.60. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -9.19 and a beta of 2.36. Sorrento Therapeutics, Inc. has a 12 month low of $4.31 and a 12 month high of $19.39. The company has a quick ratio of 2.75, a current ratio of 2.77 and a debt-to-equity ratio of 0.35.

Sorrento Therapeutics (NASDAQ:SRNE) last issued its quarterly earnings results on Wednesday, May 5th. The biopharmaceutical company reported $0.01 EPS for the quarter, missing the Zacks’ consensus estimate of $0.24 by ($0.23). Sorrento Therapeutics had a negative return on equity of 133.68% and a negative net margin of 496.04%. The business had revenue of $14.26 million for the quarter, compared to the consensus estimate of $17.25 million. On average, research analysts anticipate that Sorrento Therapeutics, Inc. will post 1.09 EPS for the current fiscal year.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc, a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system.

Read More: What is Considered a Good Return on Equity (ROE)?

Want to see what other hedge funds are holding SRNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sorrento Therapeutics, Inc. (NASDAQ:SRNE).

Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.